Upregulation of sphingosine kinase 1 in response to doxorubicin generates an angiogenic response via stabilization of Snail
The FASEB Journal · 2023
DOI: 10.1096/fj.202201066r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Joseph Bonica und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Stony Brook University, Stony Brook, New York, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Sphingosine kinase 1 (SK1) converts the pro‐death lipid sphingosine to the pro‐survival sphingosine‐1‐phosphate (S1P) and is upregulated in several cancers. DNA damaging agents, such as the chemotherapeutic doxorubicin (Dox), have been shown to degrade SK1 protein in cancer cells, a process dependent on wild‐type p53. As mutations in p53 are very common across several types of cancer, we evaluated the effects of Dox on SK1 in p53 mutant cancer cells. In the p53 mutant breast cancer cell line MDA‐MB‐231, we show that Dox treatment significantly increases SK1 protein and S1P. Using MDA‐MB‐231 cells with CRISPR‐mediated knockout of SK1 or the selective SK1 inhibitor PF‐543, we implicated SK1 in both Dox‐induced migration and in a newly uncovered proangiogenic program induced by Dox. Mechanistically, inhibition of SK1 suppressed the induction of the cytokine BMP4 and of the EMT transcription factor Snail in response to Dox. Interestingly, induction of BMP4 by SK1 increased Snail levels following Dox treatment by stabilizing Snail protein. Furthermore, we found that SK1 was required for Dox‐induced p38 MAP kinase phosphorylation and that active p38 MAPK in turn upregulated BMP4 and Snail, positioning p38 downstream of SK1 and upstream of BMP4/Snail. Modulating production of S1P by inhibition of de novo sphingolipid synthesis or knockdown of the S1P‐degrading enzyme S1P lyase identified S1P as the sphingolipid activator of p38 in this model. This work establishes a novel angiogenic pathway in response to a commonly utilized chemotherapeutic and highlights the potential of SK1 as a secondary drug target for patients with p53 mutant cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Stony Brook University, Stony Brook, New York, USA.
- Cancer Center, Stony Brook University, Stony Brook, New York, USA.
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
- Northport Veterans Affairs Medical Center, Northport, New York, USA.
- Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York, USA.
- Department of Biochemistry, Stony Brook University, Stony Brook, New York, USA.
ORCID-Profile: Joseph Bonica
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Bonica, J., Clarke, C. J., Obeid, L. M., Luberto, C., & Hannun, Y. A. (2023). Upregulation of sphingosine kinase 1 in response to doxorubicin generates an angiogenic response via stabilization of Snail. The FASEB Journal. https://doi.org/10.1096/fj.202201066r
Vancouver
Bonica J, Clarke CJ, Obeid LM, Luberto C, Hannun YA. Upregulation of sphingosine kinase 1 in response to doxorubicin generates an angiogenic response via stabilization of Snail. The FASEB Journal. 2023. doi:10.1096/fj.202201066r
BibTeX
@article{Bonica2023,
author = {Bonica, Joseph and Clarke, Christopher J and Obeid, Lina M and Luberto, Chiara and Hannun, Yusuf A},
title = {Upregulation of sphingosine kinase 1 in response to doxorubicin generates an angiogenic response via stabilization of Snail},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202201066r}
}
EUVIMED